Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients

Next Previous
Trial Profile

A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs L-DOS 47 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man
  • Sponsors Helix BioPharma

Most Recent Events

  • 13 Aug 2025 According to a Helix BioPharma media release, the company announced the publication of a peer-reviewed article in Frontiers in Oncology titled 'Safety of unconventional antibody-drug conjugate L-DOS47 in a Phase I/II monotherapy study targeting advanced NSCLC".
  • 25 Oct 2019 According to a Helix BioPharma media release, all analyses have been completed for this study and a draft clinical study report is currently under review and expected to be finalized by the end of calendar 2019.
  • 19 Mar 2018 According to a Helix BioPharma media release, this study was terminated due to lack of efficacy and the company is currently awaiting the finalized reports.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top